SOPHiA GENETICS partnering with Boundless Bio on oncogene cancer therapies

Sep. 21, 2022 9:30 AM ETSOPHiA GENETICS SA (SOPH)By: Jonathan Block, SA News Editor

Blood sample for oncogene test

jarun011/iStock via Getty Images

  • SOPHiA GENETICS (NASDAQ:SOPH) has entered a partnership with precision oncology company Boundless Bio to develop therapeutics directed against extrachromosomal DNA (ecDNA) in oncogene amplified cancers.
  • Boundless Bio is developing the first ecDNA-directed therapies (ecDTx) as well as a precision diagnostic

Recommended For You

Comments

To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.
Is this happening to you frequently? Please report it on our feedback forum.
If you have an ad-blocker enabled you may be blocked from proceeding. Please disable your ad-blocker and refresh.